Exploring New Frontiers in Cancer Treatment: The STOPGAP Trial
Updated: Sep 11
Understanding the Study
This clinical study investigated whether delivering chemotherapy directly into the abdomen, known as intraperitoneal chemotherapy, could enhance treatment outcomes for individuals with gastric (stomach) or gastroesophageal junction (GEJ) cancer. This approach was tested alongside standard chemotherapy administered through a vein. The focus was on patients whose cancer had spread to the peritoneal lining, a challenging and often difficult-to-treat stage of the disease.
Who Participated in the Study?
The study included adults diagnosed with stomach or GEJ cancer, confirmed by biopsy. These patients had cancer cells present in the abdominal cavity but no evidence of spread to other organs. All participants had undergone standard systemic chemotherapy for approximately 3–4 months. Those whose cancer remained stable were then treated with both systemic chemotherapy and intraperitoneal chemotherapy, delivered through a small implanted port.
Why Consider Intraperitoneal Chemotherapy?
Cancer cells that invade the peritoneal lining can be particularly resistant to standard intravenous (IV) chemotherapy. This is because the bloodstream often fails to deliver sufficient drug concentrations to the abdominal lining. By administering a portion of the chemotherapy directly into the abdomen, specifically intraperitoneal paclitaxel, the medical team aimed to expose the cancer cells to higher drug levels, improving disease control.
Treatment Administration
Chemotherapy was administered in two ways:
- Through an IV (into a vein) in the arm (standard systemic therapy).
- Through a port directly into the peritoneal cavity (intraperitoneal paclitaxel).
Treatments were scheduled on specific days over several weeks, repeating in cycles.
Research Goals
The primary aim of the study was to determine how many patients remained alive without their cancer worsening one year after beginning this combined treatment. Additional outcomes included overall survival rates and quality of life during treatment.
Key Findings
The combined approach of systemic chemotherapy and direct abdominal chemotherapy was feasible and could be safely administered to most eligible patients.
In some cases where the peritoneal disease responded positively, doctors considered surgery to remove visible cancer. This sometimes included heated chemotherapy during surgery (HIPEC), a more aggressive treatment option.
Although this was a Phase II study, the results indicated that this treatment strategy might better control cancer spread in the abdomen compared to systemic chemotherapy alone. It also suggested potential for prolonged survival, though larger studies are necessary for confirmation.
Implications for Patients
This trial highlights that for certain individuals with advanced stomach or GEJ cancer that has spread to the peritoneal lining, adding intraperitoneal chemotherapy to the standard regimen could be a promising strategy. It may enable stronger treatment delivery to the cancer cells in the abdomen, offering improved disease control over standard treatment alone. Ongoing studies, like the STOPGAP II trial, aim to determine whether this approach enhances long-term survival and should be integrated into routine care.
Conclusion
The STOPGAP trial represents a significant step forward in the treatment of advanced gastric and GEJ cancers. By exploring innovative methods like intraperitoneal chemotherapy, we are paving the way for potentially more effective treatment options. As we continue to gather data from larger studies, we remain hopeful about the future of cancer treatment and the possibility of improving the quality of life for patients facing these challenging diagnoses.
